Related Experiment Video
Updated: Aug 31, 2025
08:47
Evaluation of Cardiac Contractility Modulation Therapy in 2D Human Stem Cell-Derived Cardiomyocytes
Published on: December 16, 2022
2.5K
Cardiomyocyte-specific CYP2J2 and its therapeutic implications.
Robert Valencia1, Wesam Bassiouni1, Ahmed M Darwesh2
1Department of Pharmacology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada.
Expert Opinion on Drug Metabolism & Toxicology
|August 23, 2022
Summary
Cardiac CYP2J2 (Cytochrome P450 2J2) plays a key role in heart health by metabolizing fatty acids. Further research into CYP2J2 is crucial for understanding its impact on cardiac function and disease.
Area of Science:
- Biochemistry
- Cardiology
- Pharmacology
Background:
- Cytochrome P450s (CYPs) are crucial monooxygenases with varied biological functions.
- CYP2J2 is highly expressed in the heart, metabolizing polyunsaturated fatty acids (PUFA) into lipid mediators vital for homeostasis and cardioprotection.
Purpose of the Study:
- To review the current knowledge on cardiac CYP2J2.
- To assess CYP2J2-mediated cardioprotection, substrate effects, and implications of polymorphisms and sexual dimorphism.
Main Methods:
- Literature search of PubMed-MEDLINE (up to 2022).
- Evaluation of studies on cardiac CYP2J2, its modulators, substrates, and genetic variations.
Main Results:
- Cardiac CYP2J2 metabolism influences cardiac function.
- Factors like sex and age affecting CYP2J2 require further investigation for clinical relevance.
Conclusions:
- Understanding CYP2J2-derived PUFA metabolites is essential for therapeutic targeting.
- Targeting CYP2J2 presents a novel therapeutic strategy for cardiac homeostasis, drug metabolism, and cardioprotection.
Related Concept Videos
01:29Cardiomyopathy V: Interprofessional Care
29
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
29
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
244
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
244
01:30Cardiomyopathy II: Dilated Cardiomyopathy
19
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
19
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
827
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
827
02:34Inhibition of Cdk Activity
4.9K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
39
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
39